期刊文献+
共找到491篇文章
< 1 2 25 >
每页显示 20 50 100
Brain edema and tumor necrosis factor-like weak inducer of apoptosis in rats with cerebral ischemia
1
作者 Renlan Zhou Peng Xie 《Neural Regeneration Research》 SCIE CAS CSCD 2008年第12期1360-1363,共4页
BACKGROUND: Recent studies have demonstrated that tumor necrosis factor-like weak inducer of apoptosis (TWEAK) participates in brain edema. However, it is unclear whether blood-brain barrier (BBB) disruption is a... BACKGROUND: Recent studies have demonstrated that tumor necrosis factor-like weak inducer of apoptosis (TWEAK) participates in brain edema. However, it is unclear whether blood-brain barrier (BBB) disruption is associated with TWEAK during the process of brain edema OBJECTIVE: To investigate the effects of TWEAK on BBB permeability in brain edema. DESIGN, TIME AND SETTING: An immunohistochemical observation, randomized, controlled animal experiment was performed at the Laboratory of Neurosurgical Anatomy, Xiangya Medical College, Central South University & Central Laboratory, Third Xiangya Hospital, Central South University between January 2006 and December 2007. MATERIALS: A total of 48 adult Wistar rats were randomly divided into three groups: normal control (n = 8), sham-operated (n = 8), and ischemia/reperfusion (n = 32). Rats from the ischemia/reperfusion group were randomly assigned to four subgroups according to different time points, i.e., 2 hours of ischemia followed by 6 hours (n = 8), 12 hours (n = 8), 1 day (n = 8), or 12 days (n = 8) of reperfusion. METHODS: Focal cerebral ischemia/reperfusion injury was induced by middle cerebral artery occlusion (MCAO) using the suture method in rats from the ischemia/reperfusion group. Thread was introduced at a depth of 17-19 mm. Rats in the sham-operated group were subjected to experimental procedures similar to the ischemia/reperfusion group; however, the introducing depth of thread was 10 mm. The normal control group was not given any intervention. MAIN OUTCOME MEASURES: TWEAK expression was examined by immunohistochemistry; brain water content on the ischemic side was calculated as the ratio of dry to wet tissue weight; BBB permeability was measured by Evans blue extravasation. RESULTS: A total of eight rats died prior to and after surgery and an additional eight rats were randomly entered into the study. Thus 48 rats were included in the final analysis. In the ischemia/reperfusion group, TWEAK-positive cells were present in the ischemic penumbra surrounding the lamellar necrotic region in the fight cerebral hemisphere at 6 hours reperfusion and increased thereafter; by 2 days reperfusion they had reached a peak level, which was significantly higher than the sham-operated and normal control groups (P 〈 0.05). At 6 hours reperfusion, both brain water content and Evans blue extravasation showed the same tendency for change as TWEAK expression. Pearson correlation analysis results revealed that the degree of TWEAK expression was positively correlated with brain water content (r = 0.892, P 〈 0.05). CONCLUSION: The present results confirmed that TWEAK was involved in BBB disruption and participated in brain edema following cerebral ischemia. 展开更多
关键词 cerebral ischemia middle cerebral artery occlusion tumor necrosis factor-like weak inducer of apoptosis
下载PDF
Antitumor effect of tumor necrosis factor-related apoptosis inducing ligand combined with mevastatin on a human glioma cell line SWO-38
2
作者 Fei Zhong Jing Yang +1 位作者 Xiaogan Jin Guoping Sun 《Neural Regeneration Research》 SCIE CAS CSCD 2010年第5期396-400,共5页
BACKGROUND: Previous studies have reported that statins are less toxic to the human body and have greater antitumor activity; however, few studies have addressed the antitumor effect of statins combined with tumor ne... BACKGROUND: Previous studies have reported that statins are less toxic to the human body and have greater antitumor activity; however, few studies have addressed the antitumor effect of statins combined with tumor necrosis factor-related apoptosis inducing ligand (TRAIL). OBJECTIVE: To explore the effect of TRAIL combined with mevastatin on the proliferation and apoptotic cell death of a human glioma cell line SWO-38, and to study its mechanism of action. DESIGN, TIME AND SETTING: An in vitro control experiment was performed at the Central Laboratory of the Third Hospital Affiliated to Sun Yat-sen University, between January and April 2009. MATERIALS: The human SWO-38 cell line was provided by Cell Research, Department of Animal Experimental Center of Sun Yat-sen University; human recombinant soluble TRAIL by R&D, USA; and mevastatin by Sigma, USA. METHODS: SWO-38 cells were separately incubated in TRAIL (100, 200, 300, 400, and 500 tJg/L) and mevastatin (5, 10, 20, 30, and 40 pmol/L) for 72 hours. In addition, SWO-38 cells were incubated in TRAIL (300 μg/L), mevastatin (30 μmol/L), and a solution containing both TRAIL and mevastatin for 12, 24, 48 and 72 hours. MAIN OUTCOME MEASURES: Cell proliferation was detected using methyl thiazolyl tetrazolium assay; cell apoptosis was observed using Hoechst 33258 staining and fluorescence microscopy and was measured using Annexin V/propidium iodide flow cytometry; TRAIL R1/DR4 and TRAIL R2/DR5 protein expressions levels were measured using indirect immunofluorescence staining combined with flow cytometry in the recombinant soluble TRAIL (rsTRAIL, 300 tJg/L), mevastatin (30 IJmol/L) and combination groups; TRAIL R1/DR4 and TRAIL R2/DR5 mRNA expression was detected using real-time polymerase chain reaction. RESULTS: rsTRAIL, mevastatin and their combination inhibited tumor proliferation in a time- and dose-dependent manner. The proliferation inhibitory rate and apoptosis rate of human SWO-38 cells in the combined group were significantly greater than the rsTRAIL or mevastatin alone group (P 〈 0.01). TRAIL R1/DR4 and TRAIL R2/DR5 protein and mRNA expressions were increased in the combination group compared with mevastatin or rsTRAIL alone after 72 hours (P 〈 0.01). CONCLUSION: Both rsTRAIL and mevastatin inhibit the proliferation and apoptosis of the human glioma cell line SWO-38, while their combination enhances the anti-tumor effect. The mechanism of action possibly correlates to the upregulation of TRAIL R1/DR4 and TRAIL R2/DR5 mRNA expression by mevastatin, thereby enhancing the cell sensitivity to rsTRAIL. 展开更多
关键词 tumor necrosis factor-related apoptosis inducing ligand mevastatin neuroglioma cell apoptosis cell proliferation SWO-38 human glioma cells nerve factor neural regeneration
下载PDF
Expression of tumor necrosis factor related apoptosis inducing ligand receptor in glioblastoma
3
作者 Dongling Gao Zhongwei Zhao Hongxin Zhang Lan Zhang Kuisheng Chen Yunhan Zhang 《Neural Regeneration Research》 SCIE CAS CSCD 2008年第5期538-541,共4页
BACKGROUND: Receptors for tumor necrosis factor related apoptosis inducing ligand (TRAIL) include death receptor 4, death receptor 5, decoy receptor 1, and decoy receptor 2. Activation of death receptor 4 and 5 sel... BACKGROUND: Receptors for tumor necrosis factor related apoptosis inducing ligand (TRAIL) include death receptor 4, death receptor 5, decoy receptor 1, and decoy receptor 2. Activation of death receptor 4 and 5 selectively kills tumor cells. OBJECTIVE: To detect TRAIL receptor expression in glioblastoma by immunohistochemistry and RT-PCR, and to compare this expression to that in normal brain tissue. DESIGN: Observational analysis. SETTING: Department of Pathology, the First Affiliated Hospital of Zhengzhou University; Henan Tumor Pathology Key Laboratory. PARTICIPANTS: Twenty-five patients (17 males and 8 females) who received glioblastoma resection were selected from the Fifth Affiliated Hospital of Zhengzhou University, between September 2003 to June 2004. All glioblastoma samples were diagnosed pathologically. Twenty patients (12 males and 8 females) with craniocerebral injury who received normal brain tissue resection were selected in the same time period. There were no significant differences in sex and age between glioblastoma patients or between craniocerebral injury patients (P 〉 0.05). All patients and appropriate relatives provided informed consent, and this study was approved by the local research ethics committee. METHODS: Polyclonal antibody against TRAIL receptors and an immunohistochemical kit (batch number: 200502) were purchased from Boster Company, Wuhan. Immunohistochemistry: Expression of death receptor 4, death receptor 5, decoy receptor l, and decoy receptor 2 were observed in both glioblastoma and normal brain tissue. The experiment was performed according to the kit instructions, and positive staining was brown-yellow. Assessment: There were no positive signals (-); weakly positive signals, positive cells 〈 25% (+); weakly positive signals, positive cells 25%-50% (++); strongly positive signals, positive cells 50%-75% (+++); strongly positive signals, positive cells 〉 75% (++++). Evaluation: Expression levels of TRAIL receptors were estimated in both normal brain tissue and glioblastoma. Expression of decoy receptor 1 and decoy receptor 2 mRNA in glioblastoma were detected by reverse transcription polymerase chain reaction, and expression of decoy receptor in glioblastoma was estimated. MAIN OUTCOME MEASURES: Comparison of death receptor and decoy receptor protein expression between glioblastoma and normal brain tissue; decoy receptor mRNA expression in glioblastoma. RESULTS: Death receptor protein expression was strongly positive (+++) in glioblastoma, while it was weakly positive (+, ++) in normal brain tissue. Therefore, expression rate of death receptor protein in the glioblastoma was significantly higher than that in the normal brain tissue (.~ 2 = 18.48, 23.03, P 〈 0.01). Decoy receptor protein expression in the glioblastoma was significantly lower than that in the normal brain tissue ( x2 = 6.65, 18.76, P 〈 0.01). The level of decoy receptor mRNA expression in glioblastoma was significantly higher than those of protein expression ( x 2 = 9.82, 10.09, P〈 0.01). CONCLUSION: High expression of death receptor and low expression of decoy receptor are frequently observed in glioblastoma, suggesting that TRAIL receptor genes show an anti-tumor and expressive response during the initiation and development of the tumor. There are significant differences in decoy receptor expression between normal brain tissue and glioblastoma, suggesting that the restricted expression of decoy receptor in glioblastoma is regulated at the post-transcriptional level. 展开更多
关键词 GLIOBLASTOMA tumor necrosis factor related apoptosis inducing ligand apoptosis IMMUNOHISTOCHEMISTRY reverse transcription polymerase chain reaction
下载PDF
Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in glioma U87 cells
4
作者 Fei Zhong Xiangyuan Wu +5 位作者 Chunkui Shao Qu Lin Min Dong Jingyun Wen Xiaokun Ma Li Wei 《Neural Regeneration Research》 SCIE CAS CSCD 2010年第17期1319-1323,共5页
Studies have shown that tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)exhibits strong induction of apoptosis in human glioma cells.It remains unclear whether the mitochondrion pathway,an important ap... Studies have shown that tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)exhibits strong induction of apoptosis in human glioma cells.It remains unclear whether the mitochondrion pathway,an important apoptosis signaling pathway,is involved in TRAIL-induced glioma cell apoptosis.In the present study,in vitro cultured human glioma U87 cells were treated with human recombinant soluble TRAIL.Apoptosis of glioma U87 cells,mitochondrial transmembrane potential(Δψm),cytoplasmic cytochrome c concentration and changes in caspase-3,-8 and-9 activity following human recombinant soluble TRAIL treatment were investigated to determine the mechanism of glioma U87 cell apoptosis induced by TRAIL.Additionally,blocking caspase-8resulted in TRAIL-induced mitochondrion pathway activation,suggesting that TRAIL,through activating caspase-8,initiated a series of mitochondrial events and resulted in apoptosis of glioma U87 cells. 展开更多
关键词 tumor necrosis factor-related apoptosis-inducing ligand GLIOMA apoptosis MITOCHONDRIA neural regeneration
下载PDF
血清sTWEAK、Netrin-1联合APACHEⅡ评分对重型颅脑损伤患者术后预后不良的预测价值
5
作者 沈晨 施巍 +2 位作者 张元杰 杨治荣 程华怡 《国际检验医学杂志》 CAS 2024年第4期404-409,415,共7页
目的探讨血清可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)、神经轴突导向因子-1(Netrin-1)联合急性生理学与慢性健康状况评分系统Ⅱ(APACHEⅡ)评分对重型颅脑损伤患者术后预后不良的预测价值。方法选取2020年6月至2022年6月该院收治的... 目的探讨血清可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)、神经轴突导向因子-1(Netrin-1)联合急性生理学与慢性健康状况评分系统Ⅱ(APACHEⅡ)评分对重型颅脑损伤患者术后预后不良的预测价值。方法选取2020年6月至2022年6月该院收治的120例重型颅脑损伤患者,根据术后30 d预后情况分为预后良好组和预后不良组。对比两组血清sTWEAK、Netrin-1水平及APACHEⅡ评分。采用单因素和多因素Logistic回归分析重型颅脑损伤患者术后预后不良的影响因素,并据以构建血清sTWEAK、Netrin-1及APACHEⅡ评分联合应用的预测模型,受试者工作特征(ROC)曲线分析血清sTWEAK、Netrin-1水平及APACHEⅡ评分对重型颅脑损伤患者术后预后不良的预测价值。结果预后不良组的重症监护室居住时间长于预后良好组,白蛋白水平、入院时格拉斯哥昏迷评分法评分和血清Netrin-1水平低于预后良好组,多发脑挫裂伤占比、机械通气占比、入院时APACHEⅡ评分和血清sTWEAK、血清肌酐、血尿素氮水平均高于预后良好组,差异有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,多发脑挫裂伤、Netrin-1水平降低、入院时APACHEⅡ评分升高、sTWEAK水平升高为重型颅脑损伤患者术后预后不良的危险因素(P<0.05)。ROC曲线分析结果显示,血清sTWEAK、Netrin-1及APACHEⅡ评分3个指标单独及联合应用时曲线下面积及其95%CI分别为0.742(0.552~0.925)、0.731(0.488~0.963)、0.714(0.502~0.911)、0.882(0.795~0.947)。结论血清sTWEAK、Netrin-1联合APACHEⅡ评分对重型颅脑损伤患者术后预后不良具有较好的预测价值,可为临床治疗方案的制订提供参考。 展开更多
关键词 重型颅脑损伤 可溶性肿瘤坏死因子样凋亡弱诱导因子 神经轴突导向因子-1 急性生理学与慢性健康状况评分系统Ⅱ 预后
下载PDF
血清sTWEAK、sLOX-1与H型高血压合并HFpEF患者颈动脉粥样硬化的关系
6
作者 姜金钟 郭华 +2 位作者 苗维 田守森 田雯艳 《广东医学》 CAS 2024年第10期1226-1230,共5页
目的研究血清可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)、可溶性凝集素样氧化型低密度脂蛋白受体-1(sLOX-1)与H型高血压合并射血分数保留的心力衰竭(HFpEF)患者颈动脉粥样硬化的关系。方法选取2021年2月至2023年3月沧州中西医结合医... 目的研究血清可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)、可溶性凝集素样氧化型低密度脂蛋白受体-1(sLOX-1)与H型高血压合并射血分数保留的心力衰竭(HFpEF)患者颈动脉粥样硬化的关系。方法选取2021年2月至2023年3月沧州中西医结合医院收治的161例H型高血压合并HFpEF患者,按是否发生颈动脉粥样硬化分为硬化组与非硬化组。同期选取80例于我院体检的健康的志愿者作为对照组。收集受试者的临床资料,采用酶联免疫吸附法检测血清sTWEAK、sLOX-1水平,比较H型高血压合并HFpEF患者与对照组血清sTWEAK、sLOX-1水平,采用多因素logistic回归分析患者发生颈动脉粥样硬化的影响因素,受试者工作特征(ROC)曲线分析血清sTWEAK、sLOX-1对患者发生颈动脉粥样硬化的预测价值。结果161例患者中65例发生颈动脉粥样硬化,发生率为40.37%(65/161),未发生颈动脉粥样硬化者96例。两组在年龄、吸烟、血脂四项等方面比较,差异有统计学意义(P<0.05)。硬化组与非硬化组血清sTWEAK水平低于对照组,sLOX-1水平高于对照组(P<0.05);且硬化组sTWEAK水平低于非硬化组,sLOX-1水平高于非硬化组(P<0.05)。多因素logistic回归分析显示,HDL-C、sTWEAK、年龄、LDL-C、sLOX-1水平是患者发生颈动脉粥样硬化的影响因素(P<0.05)。ROC曲线显示,血清sTWEAK、sLOX-1联合检测对发生颈动脉粥样硬化的预测曲线下面积(AUC)为0.842,预测效能高于两指标单独检测。结论H型高血压合并HFpEF患者的血清sTWEAK水平下降、sLOX-1水平上升,与颈动脉粥样硬化发生有关,两者联合检测对颈动脉粥样硬化的发生具有一定预测价值。 展开更多
关键词 H型高血压 射血分数保留心力衰竭 颈动脉粥样硬化 可溶性肿瘤坏死因子样凋亡弱诱导因子 可溶性凝集素样氧化型低密度脂蛋白受体-1
下载PDF
自发性急性脑出血患者血浆sCD163/sTWEAK比值与预后的关系
7
作者 张文超 杨雪辉 +2 位作者 尹涛 王睿健 张盟盟 《天津医药》 CAS 2024年第3期297-301,共5页
目的探究自发性急性脑出血(ACH)患者血浆可溶性CD163(sCD163)/可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)比值与预后的关系。方法纳入ACH患者90例作为病例组,根据格拉斯哥预后评分将病例组分为预后不良组(38例)和预后良好组(52例);另... 目的探究自发性急性脑出血(ACH)患者血浆可溶性CD163(sCD163)/可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)比值与预后的关系。方法纳入ACH患者90例作为病例组,根据格拉斯哥预后评分将病例组分为预后不良组(38例)和预后良好组(52例);另选取同期体检健康者45例为对照组。酶联免疫吸附试验检测血浆sCD163、sTWEAK水平并计算sCD163/sTWEAK比值。分析血浆sCD163、sTWEAK水平及sCD163/sTWEAK比值与临床资料的相关性;Logistic回归分析ACH患者预后不良的影响因素;受试者工作特征(ROC)曲线分析sCD163/sTWEAK比值对ACH患者预后不良的预测价值。结果病例组血浆sCD163、sTWEAK水平及sCD163/sTWEAK比值均显著高于对照组;预后良好组上述指标均低于预后不良组(P<0.05)。预后良好组血肿体积、美国国立卫生研究院卒中量表(NIHSS)评分、高血压及幕下出血比例均低于预后不良组,低密度脂蛋白胆固醇(LDL-C)高于预后不良组(P<0.05)。相关性分析表明,血浆sCD163、sTWEAK水平及sCD163/sTWEAK比值与出血部位、血肿体积、NIHSS评分、白细胞计数、血小板计数、中性粒细胞/淋巴细胞比值(NLR)呈正相关(P<0.05)。Logistic回归分析显示,sCD163/sTWEAK比值、出血部位、血肿体积、NIHSS评分为ACH患者预后不良的影响因素(P<0.05)。ROC曲线结果表明,sCD163/sTWEAK比值评估ACH患者预后不良的AUC为0.850,敏感度和特异度分别为86.84%和69.23%。结论sCD163/sTWEAK比值在ACH患者血浆中水平较高,并与预后不良有关,该值对此类患者的预后有一定预测价值。 展开更多
关键词 脑出血 细胞因子Tweak 预后 可溶性血红蛋白清道夫受体163蛋白 可溶性肿瘤坏死因子样凋亡弱诱导因子
下载PDF
注意缺陷多动障碍患儿血清ACE2,TWEAK和CCL5水平检测及诊断价值研究
8
作者 王立宁 史亚楠 李宝广 《现代检验医学杂志》 CAS 2024年第5期152-156,167,共6页
目的 探究血清血管紧张素转换酶2(angiotensin-converting enzyme 2,ACE2),细胞因子肿瘤坏死因子样细胞凋亡弱诱导因子(tumor necrosis factor-like weak inducer of apoptosis,TWEAK)和CC趋化因子配体5(CC motif chemokine ligand 5,CC... 目的 探究血清血管紧张素转换酶2(angiotensin-converting enzyme 2,ACE2),细胞因子肿瘤坏死因子样细胞凋亡弱诱导因子(tumor necrosis factor-like weak inducer of apoptosis,TWEAK)和CC趋化因子配体5(CC motif chemokine ligand 5,CCL5)水平在注意缺陷多动障碍(attention deficit hyperactivity disorder,ADHD)患儿诊断、病情严重程度评估中的价值。方法 选取2022年10月~2023年10月在河北省儿童医院就诊的125例ADHD患儿记为ADHD组,另选105例在河北省妇幼保健中心体检的健康儿童为对照组,根据临床总体印象严重程度量表(CGI-S)将患儿分为轻中度组(n=83)和重度组(n=42)。ELISA方法检测血清ACE2,TWEAK,CCL5,促黄体生成素(LH)和催乳素(PRL)水平,联合型瑞文测验(CRT)和Conners父母症状问卷(PSQ)对患儿认知和行为状况进行评分。Spearman相关性分析重度组血清ACE2,TWEAK,CCL5与CGI-S,CRT,PSQ评分的相关性;受试者工作特征(ROC)曲线分析ACE2,TWEAK,CCL5对ADHD及严重程度的诊断价值。结果 ADHD患儿血清ACE2(284.35±92.34 pg/ml),TWEAK(2.56±0.76 pg/ml)水平低于对照组(379.23±106.28 pg/ml,3.52±1.12 pg/ml),CCL5水平(7.36±2.37ng/ml)高于对照组(5.24±1.63 ng/ml),差异具有统计学意义(t=7.244,7.703,7.753,均P<0.05);重度组患儿CRT,血清ACE2,TWEAK水平低于轻中度组(t=5.318,6.686,6.490),而PSQ,CCL5水平较高于轻中度组(t=5.220,6.134),差异具有统计学意义(均P<0.05);Spearman相关性分析结果显示,重度组患儿血清ACE2,TWEAK水平与CGI-S,PSQ评分负相关(r=-0.432,-0.453;-0.421,-0.426,均P<0.001),与CRT评分呈正相关(r=0.427,0.418,均P<0.001);CCL5与CGI-S,PSQ评分呈正相关(r=0.421,0.433,均P<0.001),与CRT评分呈负相关(r=-0.446,P<0.001)。血清ACE2,TWEAK和CCL5诊断ADHD发生的AUC分别为0.814,0.803和0.807,三者联合诊断的AUC为0.945,优于各自单独诊断(Z=5.439,4.258,5.576,均P<0.001);血清ACE2,TWEAK,CCL5诊断重度ADHD的AUC分别为0.853,0.796和0.805,三者联合诊断的AUC为0.930,优于各自单独诊断(Z=2.604,3.851,3.567,均P<0.001)。结论 血清ACE2,TWEAK在ADHD患儿血清中低表达,而CCL5高表达,三者表达水平具有相关性,并且诊断ADHD发生和严重程度具有较高的价值。 展开更多
关键词 注意缺陷多动障碍 血管紧张素转换酶2 细胞因子肿瘤坏死因子样细胞凋亡弱诱导因子 CC趋化因子配体5
下载PDF
血清Gal-3、TWEAK对精神分裂症的诊断价值及与精神症状严重程度的关系 被引量:1
9
作者 权涛涛 柏林 +1 位作者 于洋 张丹 《检验医学与临床》 2024年第6期800-804,共5页
目的研究血清半乳糖凝集素3(Gal-3)、肿瘤坏死因子样弱凋亡诱导因子(TWEAK)对精神分裂症的诊断价值及与精神症状严重程度的关系。方法选取2019年3月至2021年3月在该院诊治的96例精神分裂症患者作为病例组,以同期60例健康体检者为对照组... 目的研究血清半乳糖凝集素3(Gal-3)、肿瘤坏死因子样弱凋亡诱导因子(TWEAK)对精神分裂症的诊断价值及与精神症状严重程度的关系。方法选取2019年3月至2021年3月在该院诊治的96例精神分裂症患者作为病例组,以同期60例健康体检者为对照组,进行回顾性分析。采用酶联免疫吸附试验检测血清Gal-3、TWEAK水平。采用Pearson相关分析血清Gal-3、TWEAK水平与临床指标的相关性;采用多因素Logistic回归分析影响精神分裂症发生的因素;采用受试者工作特征(ROC)曲线分析血清Gal-3、TWEAK单项及联合检测对精神分裂症的诊断价值。结果观察组PANSS评分总分、阳性症状评分、阴性症状评分、一般精神病理学症状评分及血清Gal-3、TWEAK水平均高于对照组,差异均有统计学意义(P<0.001)。血清Gal-3、TWEAK水平与PANSS评分总分、阳性症状评分、阴性症状评分、一般精神病理学症状评分呈正相关(P<0.001)。PANSS评分总分、阳性症状评分、一般精神病理学症状评分升高及血清Gal-3、TWEAK水平升高均是精神分裂症发生的独立危险因素(P<0.001)。血清Gal-3、TWEAK联合检测诊断精神分裂症的曲线下面积为0.870(95%CI:0.831~0.919),明显高于血清Gal-3、TWEAK单项检测诊断精神分裂症的AUC[0.812(95%CI:0.769~0.847)、0.820(95%CI:0.771~0.852)],差异均有统计学意义(Z=4.345,P<0.001;Z=4.010,P=0.002)。结论精神分裂症患者血清Gal-3、TWEAK水平升高,二者与精神症状严重程度有关,血清Gal-3、TWEAK联合检测对精神分裂症具有较高的诊断价值。 展开更多
关键词 精神分裂症 半乳糖凝集素3 肿瘤坏死因子样弱凋亡诱导因子 诊断 精神症状
下载PDF
IgA肾病伴新月体形成合并肾衰竭的治疗方案比较及肾组织TWEAK的表达差异
10
作者 杨志英 王晓丹 +3 位作者 芮章茹 李文宏 代留玲 陈浩 《中国中西医结合肾病杂志》 2024年第8期683-687,I0004,共6页
目的:探讨糖皮质激素联合环磷酰胺的不同治疗方案对IgA肾病伴新月体形成合并肾衰竭患者的疗效和安全性及肾组织肿瘤坏死因子样凋亡微弱诱导剂(TWEAK)的表达差异。方法:将收治于我院的59位IgA肾病伴有新月体形成的肾衰竭患者根据治疗方... 目的:探讨糖皮质激素联合环磷酰胺的不同治疗方案对IgA肾病伴新月体形成合并肾衰竭患者的疗效和安全性及肾组织肿瘤坏死因子样凋亡微弱诱导剂(TWEAK)的表达差异。方法:将收治于我院的59位IgA肾病伴有新月体形成的肾衰竭患者根据治疗方案的不同纳入以下4组:对照组、糖皮质激素(G)组、G+环磷酰胺(C)组和G冲击+C组,观察24周各组的疗效和安全性。此外,免疫组织化学染色观察TWEAK在肾组织中的表达和分析其与临床指标的相关性。结果:G组、G+C组和G冲击+C组治疗后的24 h尿蛋白定量、血肌酐、eGFR水平均优于对照组(P<0.05)。对临床疗效进行比较,发现G组(47.06%)、G+C组(50.00%)和G冲击+C组(58.33%)总有效率均高于对照组(7.14%),差异具有统计学意义(P<0.05)。对药物安全性进行比较,3个治疗组不良反应发生率差异无统计学意义(P>0.05)。免疫组织化学分析结果显示总体有效组TWEAK表达和分布均低于无效组(P<0.05)。且TWEAK的表达量与尿红细胞数无明显相关性(P>0.05),但与尿蛋白定量、血肌酐存在正相关(P<0.05),与eGFR存在负相关(P<0.05)。结论:单用半量糖皮质激素的治疗方案是IgA肾病伴新月体形成合并肾衰竭安全有效的方案,且临床应用更具优势,并且我们发现IgA肾病患者肾组织中TWEAK的表达可能与更差的肾脏预后相关。 展开更多
关键词 IGA肾病 新月体形成 肾衰竭 糖皮质激素 环磷酰胺 肿瘤坏死因子样凋亡微弱诱导剂
下载PDF
T2DM患者血清sTWEAK、sCD40L水平与糖尿病微血管并发症的相关性分析
11
作者 尹婧婧 窦立冬 王昱 《新疆医科大学学报》 CAS 2024年第3期383-387,共5页
目的 探讨2型糖尿病(T2DM)患者血清可溶性肿瘤坏死因子(TNF)样凋亡弱诱导因子(sTWEAK)、可溶性CD40配体(sCD40L)水平与糖尿病微血管并发症(DMA)的相关性。方法 选取2021年3月-2023年3月航天中心医院收治的150例T2DM患者为研究对象,根据... 目的 探讨2型糖尿病(T2DM)患者血清可溶性肿瘤坏死因子(TNF)样凋亡弱诱导因子(sTWEAK)、可溶性CD40配体(sCD40L)水平与糖尿病微血管并发症(DMA)的相关性。方法 选取2021年3月-2023年3月航天中心医院收治的150例T2DM患者为研究对象,根据患者是否合并DMA分为DMA组(n=69)及T2DM组(n=81)。检测并比较两组患者血清sTWEAK、sCD40L水平及临床资料,采用Logistic回归分析影响T2DM并发微血管病变的危险因素,绘制受试者工作特征曲线(ROC)分析sTWEAK、sCD40L对T2DM并发微血管病变的预测价值。结果 DMA组患者血清sTWEAK、sCD40L水平均高于T2DM组(P<0.05);DMA组的病程、FPG及HbA1c、sTWEAK、sCD40L水平均高于T2DM,差异均有统计学意义(P<0.05);Logistic分析结果显示病程长、HbA1c高水平、sTWEAK高水平及sCD40L高水平均是导致T2DM并发微血管病变的独立危险因素(P<0.05)。ROC结果显示,血清sTWEAK、sCD40L单独及联合预测T2DM并发微血管病变的AUC(95%CI)分别为0.714(0.635~0.785)、0.744(0.666~0.812)、0.859(0.792~0.910),二者联合的预测效能优于单独检测(Z=2.626、2.395,P<0.05)。结论 血清sTWEAK、 sCD40L在DMA患者中均异常升高,与DMA关系密切,sTWEAK、sCD40L联合对于T2DM并发微血管病变的预测价值较高。 展开更多
关键词 2型糖尿病 可溶性肿瘤坏死因子样凋亡弱诱导因子 可溶性CD40配体 糖尿病微血管并发症
下载PDF
Role of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fnl4) axis in rheumatic diseases 被引量:1
12
作者 ZHU Li-xiu ZHANG Hai-hong +2 位作者 MEI Yi-fang ZHAO Yan-ping ZHANG Zhi-yi 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第21期3898-3904,共7页
Tumor necrosis factor (TNF)-Iike weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily of structurally related cytokines and is known to induce proliferation, migration, differentiation, apoptotic c... Tumor necrosis factor (TNF)-Iike weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily of structurally related cytokines and is known to induce proliferation, migration, differentiation, apoptotic celt death, inflammation, and angiogenesis. These physiological processes are induced by the binding of TWEAK to fibroblast growth factor-inducible 14 (Fn14), a highly inducible cell-surface receptor that is linked to several intracellular signaling pathways, including the nuclear factor-KB (NF-KB) pathway. This review discusses the role of the TWEAK-Fn14 axis in several rheumatic diseases and the potential therapeutic benefits of modulation of the TWEAK-Fn14 pathway. 展开更多
关键词 tumor necrosis Jactor-like weak inducer of apoptosis fibroblast growth[actor-inducible 14 rheumatic diseases
原文传递
血清suPAR、BDNF、sTWEAK水平与类风湿关节炎患者疾病活动度及骨密度的相关性
13
作者 王春雨 赵金英 +2 位作者 杜军 徐进 吴小芬 《医学研究与战创伤救治》 CAS 北大核心 2024年第5期488-492,共5页
目的研究血清可溶性尿激酶型纤溶酶原激活剂受体(suPAR)、脑源性神经营养因子(BDNF)、可溶性肿瘤坏死因子样细胞凋亡弱诱导因子(sTWEAK)水平与类风湿关节炎患者疾病活动度及骨密度的相关性。方法选取2021年1月至2023年7月解放军联勤保... 目的研究血清可溶性尿激酶型纤溶酶原激活剂受体(suPAR)、脑源性神经营养因子(BDNF)、可溶性肿瘤坏死因子样细胞凋亡弱诱导因子(sTWEAK)水平与类风湿关节炎患者疾病活动度及骨密度的相关性。方法选取2021年1月至2023年7月解放军联勤保障部队第九四○医院内分泌科收治的类风湿关节炎患者140例为类风湿关节炎组,以及2021年1月至2023年7月至本院体检中心体检健康者70例为对照组。评估患者组疾病活动度,测定骨密度。检测对照组和类风湿关节炎组的血清suPAR、BDNF、sTWEAK水平。根据疾病活动度水平将类风湿关节炎组患者再分为低度亚组(2.6~3.2)、中度亚组(3.2~5.1)、高度亚组(>5.1)。比较类风湿关节炎组与对照组、3个亚组的suPAR、BDNF、sTWEAK、骨密度;分析suPAR、BDNF、sTWEAK与疾病活动度、骨密度的相关性;分析suPAR、BDNF、sTWEAK联合检测在预测疾病加重风险中的价值。结果类风湿关节炎组血清suPAR、BDNF、sTWEAK高于对照组(P<0.05)。高度亚组血清suPAR、BDNF、sTWEAK明显大于中度亚组和低度亚组(P<0.05),中度亚组血清suPAR、BDNF、sTWEAK明显大于低度亚组(P<0.05)。类风湿关节炎组前臂远端、腰椎L1-4、股骨颈、髋关节的骨密度小于对照组(P<0.05)。高度组前臂远端、腰椎L1-4、股骨颈、髋关节骨密度明显小于中度亚组和低度亚组,中度亚组前臂远端、腰椎L1-4、股骨颈、髋关节骨密度明显小于低度亚组(P<0.05)。血清suPAR、BDNF、sTWEAK与疾病活动度呈正相关,与前臂远端、腰椎L1-4、股骨颈、髋关节的骨密度呈负相关(P<0.05)。联合suPAR、BDNF、sTWEAK三项指标预测疾病活动度升高风险的AUC大于单独预测的AUC(P=0.000)。结论类风湿关节炎患者suPAR、BDNF、sTWEAK与疾病活动度呈正相关,与骨密度呈负相关,联合检测suPAR、BDNF、sTWEAK可为预测患者疾病未来变化趋势提供有效指导。 展开更多
关键词 类风湿关节炎 可溶性尿激酶型纤溶酶原激活剂受体 脑源性神经营养因子 可溶性肿瘤坏死因子样细胞凋亡弱诱导因子 疾病活动度 骨密度 相关性
下载PDF
急性有机磷农药中毒继发心肌损伤的危险因素及血清Furin、sTWEAK对其的预测价值分析
14
作者 李蕊 朱伟 +1 位作者 许洁 谢亚荣 《国际检验医学杂志》 CAS 2024年第20期2480-2484,共5页
目的探讨急性有机磷农药中毒(AOPP)继发心肌损伤危险因素分析及血清弗林蛋白酶(Furin)、可溶性肿瘤坏死因子样弱凋亡诱导物(sTWEAK)的预测效能。方法选取2021年2月至2023年2月该院收治的146例AOPP患者为研究对象,入院后3 d,根据是否继... 目的探讨急性有机磷农药中毒(AOPP)继发心肌损伤危险因素分析及血清弗林蛋白酶(Furin)、可溶性肿瘤坏死因子样弱凋亡诱导物(sTWEAK)的预测效能。方法选取2021年2月至2023年2月该院收治的146例AOPP患者为研究对象,入院后3 d,根据是否继发中毒性心脏病分别分为无心肌损伤组(84例)和心肌损伤组(62例)。收集所有患者临床资料,采用单因素及多因素Logistic回归分析探讨AOPP患者继发心肌损伤的危险因素,采用酶联免疫吸附试验检测所有患者血清Furin、sTWEAK水平,并采用受试者工作特征(ROC)曲线评估血清Furin、sTWEAK对AOPP患者继发心肌损伤的预测价值。结果146例AOPP患者共有62例发生心肌损伤,发生率为42.47%。单因素分析结果显示,两组性别、服药至入院时间、农药类型比较,差异无统计学意义(P>0.05)。心肌损伤组肌钙蛋白I、肌酸激酶同工酶水平及年龄≥60岁、中毒程度为重度、急性生理学和慢性健康状况评价(APACHE)Ⅱ评分≥20分的比例高于无心肌损伤组(P<0.05)。心肌损伤组血清Furin、sTWEAK水平均高于无心肌损伤组(P<0.05)。血清Furin、sTWEAK预测AOPP患者继发心肌损伤的曲线下面积(AUC)分别为0.813、0.744,二者联合预测的AUC为0.896,高于各指标单独预测。多因素Logistic回归分析显示,中毒程度重度(OR=2.054,95%CI 1.256~3.360),APACHEⅡ评分≥20分(OR=2.323,95%CI 1.334~4.046),血清Furin≥129.48 ng/L(OR=3.380,95%CI 1.689~6.766),血清sTWEAK≥845.86 ng/L(OR=4.988,95%CI 2.057~12.097)均是影响AOPP患者继发心肌损伤的危险因素(P<0.05)。结论AOPP患者继发心肌损伤与其中毒程度及APACHEⅡ评分有关,且血清Furin、sTWEAK水平在AOPP继发心肌损伤患者中升高,对预测AOPP继发心肌损伤患者具有重要临床意义。 展开更多
关键词 急性有机磷农药中毒 心肌损伤 弗林蛋白酶 可溶性肿瘤坏死因子样弱凋亡诱导物 预测效能
下载PDF
2型糖尿病患者血清PTX3、sTWEAK水平与非酒精性脂肪性肝病的关系研究
15
作者 赵戬 朱贺 侯丹 《检验医学与临床》 CAS 2024年第7期907-911,917,共6页
目的探讨2型糖尿病(T2DM)患者血清正五聚蛋白3(PTX3)、可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)水平与非酒精性脂肪性肝病(NAFLD)的关系。方法选取北部战区总医院152例新诊断为T2DM的患者为研究对象,根据是否合并NAFLD将患者分为NA... 目的探讨2型糖尿病(T2DM)患者血清正五聚蛋白3(PTX3)、可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)水平与非酒精性脂肪性肝病(NAFLD)的关系。方法选取北部战区总医院152例新诊断为T2DM的患者为研究对象,根据是否合并NAFLD将患者分为NAFLD组(92例)和非NAFLD组(60例);根据肝脏超声检查结果,将NAFLD患者分为轻度组、中度组和重度组。另选取35例健康人作为对照(对照组)。采用酶联免疫吸附试验检测血清PTX3、sTWEAK水平。采用Pearson相关分析T2DM患者PTX3和sTWEAK水平与总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)的关系。采用多因素Logistic回归分析T2DM合并NAFLD的影响因素;采用受试者工作特征(ROC)曲线分析PTX3、sTWEAK对NAFLD的预测价值,计算曲线下面积(AUC)。比较轻度组、中度组、重度组血清PTX3、sTWEAK水平。结果与对照组比较,NAFLD组和非NAFLD组血清PTX3、sTWEAK水平较高(P<0.05)。与非NAFLD组比较,NAFLD组血清PTX3、sTWEAK水平较高(P<0.05)。体质量指数(BMI,OR=3.387)、TG(OR=1.958)、HOMA-IR(OR=3.040)、PTX3(OR=4.836)、sTWEAK(OR=4.133)是T2DM合并NAFLD的影响因素(P<0.05)。T2DM患者血清PTX3水平分别与BMI、LDL-C、FPG、HbA1c、HOMA-IR呈正相关(P<0.05),而与HDL-C呈负相关(P<0.05)。血清sTWEAK水平分别与LDL-C、FPG、HOMA-IR呈正相关(P<0.05)。血清PTX3、sTWEAK预测T2DM患者发生NAFLD的AUC分别为0.873和0.821,二者联合可将AUC提高至0.915。轻度组、中度组、重度组血清PTX3和sTWEAK水平比较,差异有统计学意义(P<0.05),病情越重,患者血清PTX3和sTWEAK水平越高。结论PTX3、sTWEAK是T2DM患者发生NAFLD的影响因素,并且血清PTX3、sTWEAK水平越高,NAFLD病情越重。 展开更多
关键词 2型糖尿病 正五聚蛋白3 可溶性肿瘤坏死因子样凋亡弱诱导因子 非酒精性脂肪性肝病 总胆固醇 甘油三酯 低密度脂蛋白胆固醇
下载PDF
前列腺癌患者血清TWEAK和SREBP-1水平表达与临床病理特征及无进展生存预后的关系研究
16
作者 姚俊波 贾波 +2 位作者 刘加元 邹一鸣 邓思文 《现代检验医学杂志》 CAS 2024年第3期136-141,共6页
目的 研究前列腺癌(prostate cancer,PC)患者血清肿瘤坏死因子样弱凋亡诱导因子(tumor necrosis factor like weak inducer of apoptosis,TWEAK)、固醇调节元件结合蛋白1(sterol regulatory element-binding protein 1,SREBP-1)表达与... 目的 研究前列腺癌(prostate cancer,PC)患者血清肿瘤坏死因子样弱凋亡诱导因子(tumor necrosis factor like weak inducer of apoptosis,TWEAK)、固醇调节元件结合蛋白1(sterol regulatory element-binding protein 1,SREBP-1)表达与临床病理特征及无进展生存预后的关系。方法 选取2018年1月~2020年1月武汉市东西湖区人民医院行PC根治术的94例PC患者为PC组,以同期50例前列腺增生(benign prostatic hyperplasia,BPH)患者为BPH组,以同期体检的50例健康人为对照组。酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELISA)检测血清TWEAK和SREBP-1表达水平。Kaplan-Meier生存分析比较血清TWEAK和SREBP-1对PC患者无进展生存预后的影响。多因素COX回归分析影响PC患者无进展生存预后的因素。结果PC组患者血清TWEAK(77.14±15.46 ng/L),SREBP-1(334.14±33.81 ng/L)高于BPH组(38.69±10.58 ng/L,201.69±28.74 ng/L)和对照组(36.26±10.27 ng/L,189.51±27.65 ng/L),差异具有统计学意义(t=23.752,25.249;34.636,37.821,均P<0.05)。PC患者血清TWEAK与SREBP-1表达呈显著正相关(r=0.668,P=0.001)。Gleason评分> 7分、TNM分期Ⅲ期及术前前列腺特异抗原(prostate specific antigen,PSA)水平≥20 ng/ml的PC患者血清TWEAK,SREBP-1水平高于Gleason评分≤7分,TNM分期Ⅰ~Ⅱ期及术前PSA水平<20 ng/ml,差异具有统计学意义(t=8.465~16.597,均P<0.05)。TWEAK高表达组和低表达组三年总体无进展生存率分别为60.42%(29/48)和86.96%(40/46),SREBP-1高表达组和低表达组三年总体无进展生存率分别为57.78%(26/45)和87.76%(43/49);TWEAK高表达组、SREBP-1高表达组三年累积无进展生存率低于TWEAK低表达组、SREBP-1低表达组,差异具有统计学意义(Log-rankχ2=8.125,9.547,P=0.004,0.002)。TNM分期Ⅲ期(OR=1.448,P <0.001)、Gleason评分> 7分(OR=1.401,P <0.001)、术前PSA≥20 ng/ml (OR=1.353,P <0.001)及血清TWEAK (OR=1.338,P <0.001)和SREBP-1 (OR=1.293,P <0.001)是影响PC患者无进展生存预后的独立危险因素。结论 PC患者血清TWEAK和SREBP-1升高,两者与PC临床病理特征相关,是评估无进展生存预后的血清标志物。 展开更多
关键词 前列腺癌 肿瘤坏死因子样弱凋亡诱导因子 固醇调控元件结合蛋白-1
下载PDF
H型高血压合并急性心肌梗死患者外周血Furin、sTWEAK、NLR与心肌损伤指标和预后不良的关系 被引量:2
17
作者 刘红艳 杜玉杰 +1 位作者 尤冉冉 孟祥慧 《疑难病杂志》 CAS 2023年第4期343-349,372,共8页
目的分析H型高血压(HHT)合并急性心肌梗死(AMI)患者外周血弗林蛋白酶(Furin)、可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)、中性粒细胞/淋巴细胞比值(NLR)与心肌损伤指标和预后不良的关系。方法选取2019年1月—2021年2月北京中医药大... 目的分析H型高血压(HHT)合并急性心肌梗死(AMI)患者外周血弗林蛋白酶(Furin)、可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)、中性粒细胞/淋巴细胞比值(NLR)与心肌损伤指标和预后不良的关系。方法选取2019年1月—2021年2月北京中医药大学房山医院心血管科收治的HHT合并AMI患者231例为HHT+AMI组,单纯HHT患者77例为HHT组,医院健康体检者52例为健康对照组。比较3组受试者外周血Furin、sTWEAK、NLR及血清心肌损伤指标[肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(cTnI)、N末端脑钠肽前体(NT-proBNP)],并分析外周血Furin、sTWEAK、NLR与心肌损伤指标的相关性。随访1年统计HHT+AMI组患者主要不良心血管事件(MACE)发生情况,采用Logistic回归分析HHT合并AMI患者发生MACE的影响因素,绘制受试者工作特征曲线(ROC)分析三者对HHT合并AMI患者发生MACE的预测价值。结果外周血Furin、sTWEAK、NLR水平比较,HHT+AMI组>HHT组>健康对照组(F/P=981.029/<0.001、1032.486/<0.001、326.617/<0.001),MACE亚组高于非MACE亚组(t/P=19.498/<0.001、17.909/<0.001、2.507/<0.001);HHT+AMI组CK-MB水平高于HHT组和健康对照组,血清cTnI、NT-proBNP水平比较,HHT+AMI组>HHT组>健康对照组(F/P=580.966/<0.001、672.830/<0.001、463.233/<0.001);外周血Furin、sTWEAK、NLR与血清CK-MB、cTnI、NT-proBNP水平均呈显著正相关(Furin:r/P=0.713/<0.001、0.604/<0.001、0.515/<0.001;sTWEAK:r/P=0.412/0.002、0.533/<0.001、0.502/<0.001;NLR:r/P=0.513/<0.001、0.554/<0.001、0.481/<0.001);KillipⅢ/Ⅳ级、Gensini评分高、Furin高、sTWEAK高、NLR高均是导致HHT合并AMI患者MACE发生的独立危险因素[OR(95%CI)=1.725(1.178~2.524)、1.571(1.160~2.128)、2.412(1.527~3.806)、2.204(1.421~3.418)、1.784(1.213~2.624)]。外周血Furin、sTWEAK、NLR及三者联合检测预测HHT合并AMI患者发生MACE的曲线下面积(AUC)分别为0.740、0.715、0.693、0.841,三指标联合预测效能优于各指标单独检测(Z/P=2.038/0.042、2.459/0.014、4.037/<0.001)。结论Furin、sTWEAK、NLR在HHT合并AMI患者外周血中均异常升高,且与心肌损伤、预后不良关系密切,三者联合检测可作为预测HHT合并AMI患者预后不良的参考依据。 展开更多
关键词 H型高血压 心肌梗死 急性 弗林蛋白酶 可溶性肿瘤坏死因子样凋亡弱诱导因子 中性粒细胞/淋巴细胞比值 心肌损伤指标 预后
下载PDF
COMBINATION OF γ-INTERFERON WITH TRAIL AND CISPLATIN OR ETOPOSIDE INDUCES APOPTOSIS IN HUMAN NEUROBLASTOMA CELL LINE SH-SY5Y 被引量:9
18
作者 Hai-xia Tong Chun-wei Lu +2 位作者 Ji-hong Zhang Li Ma Jin-hua Zhang 《Chinese Medical Sciences Journal》 CAS CSCD 2007年第1期38-43,共6页
Objective To study the effect of γ-interferon (IFNγ), tumor necrosis factor related apoptosis inducing ligand (TRAIL), and cisplatin or etoposide induced apoptosis in human neuroblastoma cell line SH-SY5Y and it... Objective To study the effect of γ-interferon (IFNγ), tumor necrosis factor related apoptosis inducing ligand (TRAIL), and cisplatin or etoposide induced apoptosis in human neuroblastoma cell line SH-SY5Y and its possible molecular mechanisms. Methods The expressions of Caspase 8 mRNA and protein were detected with RT-PCR and Western blot analysis. The effects of IFNγ, TRAIL, IFNγ + TRAIL, IFNγ + Caspase 8 inhibitor + TRAIL, IFNγ + cisplatin + TRAIL, and IFNγ + etoposide + TRAIL on the growth and apoptosis of SH-SY5Y cells were detected with the methods of MTT and flow cytometry. The relative Caspase 8 activity was measured with colorimetric assay. Results Caspase 8 was undetectable in SH-SY5Y cells but an increased expression of Caspase 8 mRNA and protein was found after treatment with IFNγ. SH-SY5Y ceils themselves were not sensitive to TRAIL, but those expressing Caspase 8 after treatment with IFNγ were. The killing effect of TRAIL on SH-SY5Y cells expressing Caspase 8 was depressed by Caspase 8 inhibitor. Cisplatin and etoposide could enhance the sensitivity of TRAIL on SH-SY5Y cells. The relative Caspase 8 activity of SH-SY5Y cells in IFNγ + TRAIL group was significantly higher than those of control group, IFNγ group, TRAIL group, and inhibitor group ( P 〈 0. 01 ). There was no significant difference among IFNγ + TRAIL group, IFNγ + cisplatin + TRAIL group, and IFNγ + etoposide + TRAIL group. Conclusions IFNγ could sensitize SH-SY5Y cells to TRAIL-induced apoptosis and this may be realized by the up-regulation of Caspase 8. Cisplatin and etoposide could enhance the killing effect of TRAIL on SH-SY5Y cells. 展开更多
关键词 NEUROBLASTOMA apoptosis tumor necrosis factor related apoptosis inducing ligand γ-interferon
下载PDF
Apoptosis and Expression of Protein TRAIL in Granulosa Cells of Rats with Polycystic Ovarian Syndrome 被引量:5
19
作者 张娟 朱桂金 +2 位作者 王昕荣 徐蓓 胡琳莉 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2007年第3期311-314,共4页
The relationship between apoptosis of granulosa cells and follicle development arrest in polycystic ovarian syndrome (PCOS) rats, and the contribution of tumor necrosis factor related apoptosis inducing ligand (TRAIL)... The relationship between apoptosis of granulosa cells and follicle development arrest in polycystic ovarian syndrome (PCOS) rats, and the contribution of tumor necrosis factor related apoptosis inducing ligand (TRAIL) in apoptosis of granulosa cells were explored. By using sodium prasterone sulfate rat PCOS model was induced. The apoptosis of granulosa cells in ovaries of rats was observed by TdT-mediated dUTP-biotin nick end-labeling (TUNEL), and the expression of TRAIL protein and mRNA in granulosa cells was detected by using immunhistochemical staining and reverse transcription polymerase chain reaction (RT-PCR) respectively. The apoptotic rate and the expression of protein TRAIL in granulosa cells were significantly higher in antral follicles from the PCOS rats than in those from the control rats (P<0.01, P<0.05). There was no significant difference in apoptotic rate and the expression of TRAIL protein in granulosa cells of preantral follicles between the PCOS rats and the control rats (P>0.05). No apoptosis and the expression of TRAIL protein in granulosa cells of primordial follicles were found in the two groups. The expression of TRAIL mRNA was significantly stronger in granulosa cells from the PCOS rats than in those from the con- trol rats (P<0.01). It was suggested that the apoptotic rate in granulosa cells was significantly higher in antral follicle from the PCOS rats than in those from the control rats. TRAIL played a role in regu- lating the apoptosis of granulosa cells in PCOS rats. 展开更多
关键词 tumor necrosis factor related apoptosis inducing ligand granulosa cell apoptosis polycystic ovarian syndrome RAT
下载PDF
TNF related apoptosis-inducing ligand and its receptors in ocular tumors 被引量:1
20
作者 Qian Ning, Xin-Han Zhao 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2011年第5期552-557,共6页
Most of the ocular tumors have poor prognosis, and they remain a difficult problem in the area of ophthalmology. With the rapid development of molecular biology and immunologic techniques and the deep research on ocul... Most of the ocular tumors have poor prognosis, and they remain a difficult problem in the area of ophthalmology. With the rapid development of molecular biology and immunologic techniques and the deep research on ocular tumor related genes, it becomes possible to diagnose and treat malignant tumors from the molecular level. The tumor necrosis factor related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor (TNF) super family, is a promising candidate, either alone or in combination with established cancer therapies, since it can initiate apoptosis through the activation of their death receptors. The ability of TRAIL to selectively induce apoptosis of transformed, virus-infected or tumor cells but not normal cells promotes the development of TRAIL-based cancer therapy. Here, we will review TRAIL and its receptors' structure, function, mechanism of action and application in ocular tumors therapy. 展开更多
关键词 tumor necrosis factor related apoptosis-inducing ligand ocular tumors apoptosis
下载PDF
上一页 1 2 25 下一页 到第
使用帮助 返回顶部